The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.
The goal of this grant program is to foster preclinical and patient-based research into how incretin mimetics, including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents, influence cancer risk. This research aims to understand the mechanistic impacts of these agents beyond their known effects on weight loss and diabetes, given preliminary evidence suggesting they may affect the risk of various obesity-related cancers differently. The program seeks to attract skilled scientists to delve into the mechanisms by which these agents modulate cancer risk.